

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/030,985	02/26/1998	LOUIS D. FALO JR	214001-00648	8081
7:	590 ° 09/05/2002			
STEPHEN A BRENT FOLEY & LARDNER WASHINGTON HARBOUR			EXAMINER	
			EWOLDT, GERALD R	
	T NW SUITE 500 N, DC 20007-6109		ART UNIT	PAPER NUMBER
	•		1644	27
			DATE MAILED: 09/05/2002	27

Please find below and/or attached an Office communication concerning this application or proceeding.



Office Action Summary

Application No. **09/030,985**

Applicant(s

Falo et al.

Examiner

G.R. Ewoldt

Art Unit **1644**



	- The MAILING DATE of this communication appears	on the cover sl	heet with	the correspondence address		
Period 1	for Reply					
	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.	TO EXPIRE _	1	_MONTH(S) FROM		
	ions of time may be available under the provisions of 37 CFR 1.136 (a). In	no event, however,	may a reply b	e timely filed after SIX (6) MONTHS from the		
- If the p - If NO p - Failure - Any re	plate of this communication. Deriod for reply specified above is less than thirty (30) days, a reply within the period for reply is specified above, the maximum statutory period will apply a to reply within the set or extended period for reply will, by statute, cause the ply received by the Office later than three months after the mailing date of the patent term adjustment. See 37 CFR 1.704(b).	and will expire SIX (6 ne application to beco) MONTHS frome ABANDO	rom the mailing date of this communication. ONED (35 U.S.C. § 133).		
Status						
1) [X]	Responsive to communication(s) filed on Jul 12, 20)02		·		
2a) 💢	This action is FINAL . 2b) \square This act	ion is non-fina	l.			
3) 🗆	Since this application is in condition for allowance eclosed in accordance with the practice under Ex pair	•		•		
Disposi	tion of Claims					
4) 💢	Claim(s) 13-15, 17-24, 37, and 38			is/are pending in the application.		
4	la) Of the above, claim(s)			is/are withdrawn from consideration.		
5) 🗆	Claim(s)			is/are allowed.		
	Claim(s)			•		
	Claim(s)					
8) 💢	Claims <u>13-15, 17-24, 37, and 38</u>	ar	e subject	to restriction and/or election requirement.		
Applica	tion Papers					
9) 🗆	The specification is objected to by the Examiner.					
10)□	The drawing(s) filed on is/are	a) 🗆 accepto	ed or b)[\sqsupset objected to by the Examiner.		
	Applicant may not request that any objection to the d	rawing(s) be he	eld in abe	yance. See 37 CFR 1.85(a).		
11)	The proposed drawing correction filed on	is	:: a) □ a	pproved b) \square disapproved by the Examiner.		
	If approved, corrected drawings are required in reply t	to this Office a	ction.	_		
12)	The oath or declaration is objected to by the Exami	ner.				
Priority	under 35 U.S.C. §§ 119 and 120					
13)	3) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) [☐ All b)☐ Some* c)☐ None of:					
	1. \square Certified copies of the priority documents hav	e been receive	ed.			
	2. \square Certified copies of the priority documents hav	e been receive	ed in App	lication No.		
	3. Copies of the certified copies of the priority do application from the International Bures	ocuments have au (PCT Rule	e been re 17.2(a)}.	ceived in this National Stage		
*S	ee the attached detailed Office action for a list of the	e certified cop	ies not re	eceived.		
14) 🗌	Acknowledgement is made of a claim for domestic	priority under	35 U.S.	C. § 119(e).		
a) [The translation of the foreign language provisiona		•			
15)	Acknowledgement is made of a claim for domestic	priority under	35 U.S.	C. §§ 120 and/or 121.		
Attachm						
_	tice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).				
_	tice of Draftsperson's Patent Drawing Review (PTO-948)		Notice of Informal Patent Application (PTO-152)			
31 [Inf	ormation Disclosure Statement(s) (PTO-1449) Paper No(s)	6) Other:				

Serial No. 09/030,985 Art Unit 1644

DETAILED ACTION

- 1. This application contains inventions drawn to patentably distinct species. Applicant is required under 35 U.S.C. § 121 to elect:
- A) a **specific** second cell, such as a tumor cell or a virally infected cell,
- B) and list all Claims readable thereon including those subsequently added. Currently Claims 13-14, 17-24 and 37-38 are generic.
- 2. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

The different second cells comprise significantly different biological properties when cultured with dendritic cells. In particular, virally infected cells, e.g., HIV infected T cells, can infect dendritic cells and thus render them pathogenic, whereas tumor cells are not contagious and cannot infect dendritic cells. Therefore, the species are independent and patentable over one another.

- 3. Applicant is advised that the response to this requirement to be complete must include an election of the species to be examined even though the requirement be traversed.
- 4. Any inquiry concerning this communication from the examiner should be directed to Dr. Gerald Ewoldt whose telephone number is (703) 308-9805. The examiner can normally be reached Monday through Thursday from 7:30 am to 5:30 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973.

G.R. Ewoldt, Ph.D. Patent Examiner

Technology Center 1600

September 5, 2002